Gene Editing Breakthroughs Raise Hope—and Hard Questions for the Future of Medicine

Health & Science, April 12, 2026 : Gene editing is rapidly transforming modern medicine, offering unprecedented possibilities to treat and even cure life-threatening diseases. A striking example of this progress emerged in August 2024, when a baby named KJ Muldoon in the United States became the recipient of a fully personalised gene-editing therapy designed specifically for his rare and fatal condition.

Born with an ultra-rare genetic disorder that caused toxic ammonia to accumulate in his blood, KJ faced grim prospects. Traditional options were limited to a liver transplant or palliative care. Instead, doctors pursued a groundbreaking approach—creating a customised gene-editing treatment tailored exclusively to his DNA.

At the Children’s Hospital of Philadelphia, paediatrician Dr Rebecca Ahrens-Nicklas worked alongside Dr Kiran Musunuru of the University of Pennsylvania to develop this therapy. Using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology, scientists corrected a single faulty genetic “letter” responsible for disrupting a crucial liver enzyme. Remarkably, the entire process—from designing the therapy to delivering it—was completed in just six months. KJ’s recovery was encouraging: he gradually improved and was eventually discharged after spending 307 days in hospital.

This case represents a turning point in the evolution of medical science. Earlier gene-editing treatments were designed for groups of patients suffering from the same condition, such as sickle cell disease or beta thalassaemia. KJ’s treatment, however, was uniquely individualised, signalling a shift towards personalised genetic medicine.

The foundations of this revolution were laid in 2020, when Dr Jennifer Doudna and Dr Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for developing CRISPR-Cas9 technology. This innovation enabled scientists to precisely edit DNA—the fundamental code of life—opening doors that were once confined to science fiction. However, such power has also sparked deep ethical debates, including the concern of whether humanity is “playing God.”

These concerns intensified in 2018, when Chinese scientist He Jiankui announced the birth of the world’s first gene-edited babies, claiming to have modified their DNA to provide resistance to HIV. The announcement triggered global outrage, with scientists condemning the experiment for its ethical violations and lack of transparency. The episode remains a cautionary example of how transformative technologies can be misused.

Today, gene editing is being explored across a wide range of medical fields. Scientists are engineering immune cells, such as CAR-T cells, to better detect and destroy cancer cells, with clinical trials underway for certain leukaemias, lymphomas and solid tumours. Research is also advancing in neurological conditions like Huntington’s disease and inherited forms of blindness.

However, most existing therapies differ significantly from the approach used in KJ Muldoon’s case. Many treatments involve editing cells outside the body and are standardised for broader patient groups. In contrast, KJ’s therapy was delivered directly into his body and tailored exclusively to his genetic profile, making it far more complex, costly and time-sensitive.

Despite its promise, gene editing carries real risks. Unintended “off-target” changes in DNA could lead to serious complications, including cancer. The high cost of such treatments raises concerns about accessibility and equity, while ethical questions persist around informed consent and the potential misuse of the technology for non-medical genetic enhancement.

For countries like India, the implications are particularly significant. With a high prevalence of genetic disorders such as sickle cell disease, thalassaemia and rare metabolic conditions, gene editing offers hope for transformative treatments. At the same time, it underscores the need for strong regulatory frameworks, ethical oversight, and investments in healthcare infrastructure to ensure equitable access.

Gene editing is no longer a distant possibility—it is an emerging reality reshaping the future of medicine. As scientific capabilities advance, the challenge lies not in whether we can rewrite life, but in ensuring that such power is used responsibly, ethically and for the benefit of all.